| Document |
Document Title |
|
WO/2022/017429A1 |
Provided is a chimeric antigen receptor for pathogens, The chimeric antigen receptor comprises: (a) an extracellular domain comprising one or more antigen binding regions having pathogen-related antigen specificity; (b) a transmembrane d...
|
|
WO/2022/020342A1 |
Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.
|
|
WO/2022/013743A1 |
The subject of invention is a veterinary composition comprising an essential oil, characterised in that the essential oil is selected from the group comprising anise oil, cinnamon oil, tarragon oil, clove oil, dill oil, Balsam of Peru, B...
|
|
WO/2022/013323A1 |
A composition for use in treating helminth infestation in a non-human mammal is a described. The composition comprises an antihelmintically effective amount of α-hederin and a pharmaceutically acceptable carrier. The α-hederin is provi...
|
|
WO/2022/014654A1 |
The present invention provides: a therapeutic and/or prophylactic agent for African swine fever (ASF) that contains 5-aminolevulinic acid (ALA), a derivative thereof or a salt of the same; and a therapeutic and/or prophylactic method for...
|
|
WO/2022/013744A1 |
The subject of invention is a veterinary composition comprising an essential oil, characterised in that the essential oil is selected from the group comprising parsley seed oil, lovage seed oil, celery seed oil, and wherein the said esse...
|
|
WO/2022/015240A1 |
The present invention relates to an isolated peptide, comprising or consisting of a glycine and arginine-rich (GAR/RGG) region with alarmin and/or cell penetrating activity, bioactive fragments or mutants thereof, and compositions compri...
|
|
WO/2022/008784A1 |
Use of simple acyclic polyamines for the treatment of parasites of the family Trypanosomatidae. The present invention provides the use of certain simple acyclic polyamines of Formula (I), attached to heterocycles, for the treatment of le...
|
|
WO/2022/008639A1 |
The application relates to 2-imino-hexahydropyrimidin-4-one derivatives of formula (I) which are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful for the treatment of ma...
|
|
WO/2022/008708A1 |
The present invention relates to a veterinary composition comprising artesunate or a salt thereof, and a pharmaceutically acceptable excipient, for use for preventing and/or treating leishmaniosis in a dog.
|
|
WO/2022/008761A1 |
The present invention relates to active substances against protozoa, especially against Plasmodium spp., e.g. against Plasmodium falciparum, Plasmodium vivax, P. malariae, P. ovale, P. knowlesi, against Toxoplasma spp., e.g. Toxoplasma g...
|
|
WO/2022/004877A1 |
This invention addresses the problem of developing and providing a coccidiosis control agent that has exceptional anticoccidial activity and that can prevent a mass epidemic of coccidiosis, and a method for using said coccidiosis control...
|
|
WO/2022/004620A1 |
Provided are a method for manufacturing a composition that includes antigen-specific antibody-producing cells whereby a novel vaccine strategy can be realized, a method for manufacturing a vaccine composition, a cell separation kit, and ...
|
|
WO/2021/263162A1 |
A method and compound for altering the status of both innate and adaptive immune pathways in both animals and humans are disclosed. The status alteration results in the immune response being primed whereby an accelerated and more robust ...
|
|
WO/2021/259997A1 |
The present invention relates to novel heteroaryl-substituted pyrazine derivatives of the general formula (I), in which the structural elements R1, R2, R3, R4, R5 and R6 have the meaning given in the description, to formulations and comp...
|
|
WO/2021/262621A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein G is and A1, A2, A3, A4, A5, R1, R3, m, X, X1, X2 and J are as defined in the disclosure. Also disclosed are compositio...
|
|
WO/2021/257665A1 |
Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen...
|
|
WO/2021/258056A1 |
Disclosed is a process for removing water soluble extractives from non-woody plants of the genus Hesperaloe, wherein the extract contains at least one saponin. The process includes providing Hesperaloe biomass, milling and washing the bi...
|
|
WO/2021/257880A1 |
Disclosed herein are active ingredients, compositions, and methods for increasing lifespan, for preventing or treating an aging-related disorder, for reducing a symptom of aging, and/or boosting an immune system in a mammal. Also disclos...
|
|
WO/2021/258055A1 |
Disclosed are novel pharmaceutical, animal feed compositions and methods of treating non-human animals comprising at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s), or mixtures ther...
|
|
WO/2021/252505A1 |
Provided are compounds with the following structure: Formula (I), and methods of making and using same. The methods of using the compounds may be methods for treating or prophylaxis of a cryptosporidium infection.
|
|
WO/2021/252583A1 |
The present invention is directed to a polymer platform comprising poly(L-lysine succinylated) which specifically targets scavenger receptor A1. This platform may be used to conjugate different types of drugs to the polymer for treatment...
|
|
WO/2021/245207A1 |
The present invention concerns an E. coli strains expressing high level of α-Gal, in particular selected in the group consisting of E. coli Nissle 1917 strain, E. coli O111 strain, E. coli O86: B7 strain, and mixture thereof, as a probi...
|
|
WO/2021/242581A1 |
This invention provides for compounds of the formula (I): wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation ...
|
|
WO/2021/241898A1 |
The present invention relates to a veterinary medicine and, specifically, to a veterinary orally-disintegrating-film formulation capable of treating or preventing infection or invasion of internal/external parasites in animals. The veter...
|
|
WO/2021/233967A1 |
The present invention relates to injectable compositions comprising the combination of an isoxazoline compound as well as a physiologically active macrocyclic lactone such as moxidectin.
|
|
WO/2021/236911A1 |
Provided are compounds of Formula (I) for the treatment of infectious and inflammatory diseases. The compounds described herein are lincosamides modified at the amino acid (southern) region. The compounds may have further modification at...
|
|
WO/2021/228594A1 |
The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting ...
|
|
WO/2021/222964A2 |
The present invention relates to a method of forming immunogenic complexes, in particular a method of coating pathogens or fragments thereof with hMBL or portions thereof. Furthermore, the invention relates to said immunogenic complexes,...
|
|
WO/2021/224491A1 |
The present invention is in the field of therapeutic drugs to treat malaria. In particular, the invention provides trilobine derivatives per se, and trilobine derivatives for use in the treatment of malaria, for example drug-resistant ma...
|
|
WO/2021/225551A1 |
The present invention relates to use of extracellular vesicles obtained from macrophages infected with parasites as immunotherapeutic and prophylactic agents in the disease Leishmaniasis. The objective of the invention is the use of a dr...
|
|
WO/2021/213483A1 |
An application of a series of compounds in controlling or killing mites. It has been found by comparison that the compounds, when compared with a control group, can reduce the survival time of mites; in particular, taraxerol, diosmetin, ...
|
|
WO/2021/214544A1 |
An Oral Delivery System (ODS) of the reservoir or plaster or adhesive type for administrating Hydroxychloroquine and/or Chloroquine for the treatment of rheumatoid arthritis, lupus erythematosus, SARS CoV-2, porphyria cutanea tarda for 1...
|
|
WO/2021/215393A1 |
Provided is the compound, or a salt thereof, represented in formula (I). (In formula (1): Ar indicates a C6-10 aryl group, etc.; R1 indicates a cyano group, a thiocarbamoyl group, etc.; R2 indicates a hydrogen atom, etc.; R 3 indicates a...
|
|
WO/2021/209493A2 |
The present invention relates to a composition for use in preventing an infection, or treating an infection, or treating a disease caused by an infection, the composition comprising a compound selected from the group consisting of chitos...
|
|
WO/2021/209003A1 |
The invention provides for Compound I or a pharmaceutically acceptable salt thereof (I) for use in the prevention and/or treatment of an organ injury, or a condition associated with an organ injury, in a subject diagnosed with, or suffer...
|
|
WO/2021/209265A1 |
The invention relates to compounds of formula (I), wherein the variables are as defined in the specification. It also relates to the use of compounds of formula (I) as an agrochemical pesticide; to pesticidal mixtures comprising compound...
|
|
WO/2021/209477A1 |
The present invention relates to novel crystalline of 4-[(7-chloro-2- methoxy benzo[b][ 1, 5]na phthy rid in-10-yl)amino]-2,6-bis(pyrrolid in-1 - ylmethyOphenol and salts thereof, as well as processes of manufacturing the same, and pharm...
|
|
WO/2021/203168A1 |
Provided herein are methods for treating or preventing a condition, and/or symptom or clinical manifestation, associated with systemic infection wherein a subject is intravenously administered ascorbic acid or a pharmaceutically acceptab...
|
|
WO/2021/205303A1 |
A formulation is disclosed comprising at least one ozonated oil for use in the prevention and/or treatment of leishmaniasis in a mammal.
|
|
WO/2021/203165A1 |
The invention relates to a composition for treating and/or inhibiting an infestation of a subject by an ectoparasite. The composition comprises bacterial organisms which are active against the ectoparasite and bacterial organisms which e...
|
|
WO/2021/204952A1 |
The present invention is related to new derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to dihydroisoquinoline derivatives useful for the preparation of a ...
|
|
WO/2021/204409A1 |
The present invention relates to tablet dosage formulations of oleyl phosphocholine for oral administration and the processes for their preparation. Specifically, the present invention provides a process for preparing an oleyl phosphocho...
|
|
WO/2021/200934A1 |
The present invention provides a compound indicated by formula (I) or a salt thereof that is useful for the prevention or treatment of malaria (in the formula, each of the symbols is as defined in the specification).
|
|
WO/2021/198041A1 |
The present invention provides a pharmaceutical composition consisting of: a first pharmaceutically active portion consisting of hydroxychloroquine or a salt thereof and/or chloroquine or a salt thereof; a second pharmaceutically active ...
|
|
WO/2021/191882A1 |
The present disclosure relates to compound of the formula I; or a pharmaceutically acceptable salt, ester, solvate thereof, for use in medicine, in particular as antimalarial agent. The present disclosure also relates to methods to obtai...
|
|
WO/2021/195493A1 |
Methods, devices, and systems for temperature management of a patient having a viral infection or suffering from sepsis are disclosed. Methods, devices, and systems for raising a regional temperature of the patient to and/or actively mai...
|
|
WO/2021/192393A1 |
Malaria transmission-blocking vaccines with good preservation stability and immunostimulatory action are provided. According the present invention, combination use of a pharmaceutical composition comprising (4E,8E,12E,16E,20E)-N-{2-[{4-[...
|
|
WO/2021/185154A1 |
A pharmaceutical composition comprising tizoxanide and choline hydroxide, a choline salt of tizoxanide and crystal form thereof, and a pharmaceutical use thereof. A mixture of tizoxanide and choline hydroxide, or a salt thereof and cryst...
|
|
WO/2021/188066A1 |
The present invention relates to a nutraceutical or pharmaceutical homogeneous composition having antibacterial, antifungal, antiviral, immune system reinforcing, anticancer and antiparasitic characteristics. Said homogeneous composition...
|
